• Home
  • Contact
(800) 605-8422 Toll Free
Diagnomics
×
  • Consumer Genomics Solutions
  • Analysis Platform
    • MICROARRAY
    • NGS
    • OPENARRAY
  • Research Services
    • CLINICAL/TRANSLATION RESEARCH
    • ASSAY DEVELOPMENT
    • Bioinformatics
    • Diagnomics on Cloud
    • My AccuGenie
  • News
    • Diagnomics
    • Amazing Science
  • About us
    • Terms of Service
    • Privacy Policy

Diagnomics Introduces ACMG 59 Reports for Personalized Genetic Testing

January 29, 2019AdminDiagnomics

Diagnomics, a leading genetic testing company, has developed a new ACMG 59 report that is available to healthcare providers and their patients to complement Diagnomics’ portfolio of Personalized Genomics. Diagnomics has partnered with Fabric Genomics to use Fabric Enterprise, its clinical decision-support platform, to generate clinical insights for the report. Fabric Genomics is the leading provider of genomic interpretation and clinical decision-support software. Their end-to-end software platform provides accurate interpretation for hereditary disease and oncology and allows management and scaling up of genetic workflows from initial testing to final reports. This joint initiative between the two companies is another achievement in making preventive care and personalized medicine widely available across multiple platforms that support genomic solutions.

“At Fabric Genomics, we are passionate about enabling clinical genomic testing at scale,” Martin Reese, Ph.D., CEO of Fabric Genomics commented. “We are excited to announce our partnership with Diagnomics with this first ACMG 59 report, which provides clinical insights across a number of actionable genes and related conditions.”

The report offers insights on pathogenic and likely pathogenic variants found within the set of 59 core health genes as recommended by the American College of Medical Genetics and Genomics (ACMG). The analysis is generated from Illumina’s Global Screening Array-based assay and other clinical genomic data. Detected variants are evaluated using genotype quality, minor allele frequency, and curated clinical databases for pathogenicity. The genes included in this report adhere to ACMG’s secondary findings recommendations, most recently updated on November 2016.

Although these recommendations were previously reserved for special cases of high-risk patients, Diagnomics has taken a clinically innovative approach in making the ACMG 59 accessible to all patients. The availability and transparency of information between physicians and patients will play a critical role in supporting clinical decision-making, which will have a significant impact on saving lives, leveraging resources, and lowering healthcare costs.

“We continue to invest in personalized genomics analysis capability and are delighted by our collaboration with Fabric Genomics,” Byung-In Lee, Ph.D., CEO of Diagnomics announced. “We have applied innovative strategies to make an expansive test panel both accessible and affordable for clinical use.”

Diagnomics’ mission to bridge preventive medicine and genetic testing with actionability has engendered the advancement of clinical resources for healthcare providers in empowering their patients to be proactive and make informed decisions concerning their care. The ACMG 59 report serves to highlight the company’s commitment to accessibility and applicability of personalized genomics to the individual and the healthcare community.

About Diagnomics, Inc

Diagnomics, Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. Diagnomics strives to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market. Diagnomics is a CLIA-certified, CAP-accredited laboratory providing genetic testing platform services and highly secure HIPAA-compliant cloud-based analysis solutions. To learn more, visit www.diagnomics.com.

Recent Posts

  • Diagnomics Releases Cardiovascular Health Panel on Clinical Microarray Platform
  • Visit our booth #643 at ASHG 2019, October 15-17 in Houson!
  • Diagnomics Added CLIA Certificates From Maryland, Pennsylvania, and Rhode Island
  • Visit our booth #1107 at ACMG 2019, April 3 – 5 in Seattle!
  • Diagnomics Introduces ACMG 59 Reports for Personalized Genetic Testing

Recent Comments

    Archives

    • October 2019
    • September 2019
    • March 2019
    • January 2019
    • November 2018
    • October 2018
    • September 2018
    • July 2018
    • March 2018
    • April 2017
    • December 2016
    • June 2016
    • May 2016

    Categories

    • Amazing Science
    • Diagnomics

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Diagnomics Mission

    Diagnomics Mission

    Diagnomics, Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. We strive to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market.

    Diagnomics is a CLIA-certified, CAP-accredited, and HIPAA-compliant laboratory providing genetic testing platform services and cloud-based analysis solutions.

    (800) 605-8422

    info@diagnomics.com

    www.diagnomics.com

    5050 Murphy Canyon Rd ste 150, San Diego, CA 92123

    Latest News

    • Diagnomics Releases Cardiovascular Health Panel on Clinical Microarray Platform Oct 7

      SAN DIEGO, October 7, 2019 (Newswire.com) –​Diagnomics Inc., a San...

    • Visit our booth #643 at ASHG 2019, October 15-17 in Houson! Sep 16

      Don’t miss out the largest human genetics meeting in the...

    • Diagnomics Added CLIA Certificates From Maryland, Pennsylvania, and Rhode Island Sep 9

      Diagnomics, a leading genomics services provider, announced that it now...

    • Visit our booth #1107 at ACMG 2019, April 3 – 5 in Seattle! Mar 20

       

    Legal Info

    Research Consent
    Copyright ©2018 all rights reserved
    Diagnomics, Inc.